EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized.

Slides:



Advertisements
Similar presentations
BIFURCATION LESIONS Dr. Tahsin.N
Advertisements

Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial Featured Article: José Luis Lázaro-Martínez,
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Unresolved issues with Drug-eluting Stents Stent Thrombosis Advanced Angioplasty 2007 Dan Blackman Yorkshire Heart Centre.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.
Intravenous Erythropoietin in Patients with ST-Segment Elevation MI -- Study performed by: Najjar et al -- Presented by: Jay Hall PA-SII, Ali Rahimi MD.
Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session.
The impact of PCI for concurrent CTO on left ventricular function in STEMI patients José PS Henriques, MD Academic Medical Center of the University of.
The impact of PCI for concurrent CTO on left ventricular function in STEMI patients José PS Henriques, MD Academic Medical Center of the University of.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
(p for noninferiority = 0.01)
The American College of Cardiology Presented by Dr. Adnan Kastrati
Complex Coronary Cases
Heart attack:the journey
For the HORIZONS-AMI Investigators
CARIN Trial design: Patients undergoing coronary angiography were randomized in a 1:1:1:1 fashion to CMX mg/kg, 3.6 mg/kg, 4.8 mg/kg, or placebo.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Contemporary Outcomes with Chronic Total Occlusion Revascularization
DES Should be Used as the Default Stent in ACS!
Mortality Related to Periprocedural MI in CTO-PCI
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
CathPCI-NCDR Registry Mortality (STEMI)
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Emerging Data on ACS Management From ACC
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Giuseppe Biondi Zoccai
Angiography-guided PCI
EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.
FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.
Preventive Angioplasty in Myocardial Infarction Trial
ARNO TRIAL (Antithrombotic Regimens aNd Outcome)
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.
Total lesions on MRI at 48 hours
Main branch restenosis at 1 year
(p = 0.32 for noninferiority)
Impedence-guided management
Mancini JG, et al. Am J Cardiol.
The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months. The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months.
ACC/SCAI – i2 Summit Late Breaking Clinical Trials March 29, 2008
Ischemic Postconditioning
Metoprolol for AR Trial design: Patients with chronic asymptomatic severe aortic regurgitation (AR) were randomized to metoprolol CR/XL 200 mg or matching.
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
Remote ischemic preconditioning
STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization  Lorenzo Azzalini,
The Power of As-Treated Analyses
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized to CTO-PCI within 7 days or conservative management. They were followed for 4 months. Results (p = 0.6) LVEF at 4 months: CTO-PCI vs. conservative: 44.1% vs. 44.8%, p = 0.6; LVEDV: 215.6 vs. 212.8 ml, p = 0.70 MACE at 4 months: 5.4% vs. 2.6%, p = 0.21 Periprocedural complications in CTO arm: Dissections: 13, tamponade 1, emergency CABG/ stroke/death: 0 % Conclusions Routine CTO-PCI performed within 1 week of primary PCI for STEMI does not result in improved LV function or clinical outcomes over an intermediate period of follow-up Final LVEF at 4 months CTO-PCI (n = 150) Conservative (n = 154) Presented by Dr. Jose Henriques at TCT 2016